Exciva raises €51.0M Series B round
20 January 2026· Heidelberg, Germany· health, neuroscience, biotech, b2b, deep_hardware
The proceeds will primarily fund a Phase 2 clinical trial of Deraphan for the treatment of agitation in patients with Alzheimer's disease across Europe, the UK, the US, and Canada.
Investors
LeadGimv
Also participating
EQT Life SciencesFountain Healthcare PartnersLifeArc VenturesCarma FundModi VenturesAndera PartnersLBBW Venture Capital
About Exciva
Stage
Series B
Headquarters
Heidelberg, Germany
Founded
2016
Team Size
6–20
Sectors
healthneurosciencebiotechb2bdeep_hardware